<DOC>
	<DOCNO>NCT02736188</DOCNO>
	<brief_summary>This open-label extension study Ace-ER ass long-term safety efficacy Ace-ER treatment period 24 month . Approximately 165 subject UX001-CL202 , UX001-CL301 UX001-CL203 study eligible enroll study .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy Ace-ER Tablets Patients With GNE Myopathy Hereditary Inclusion Body Myopathy</brief_title>
	<detailed_description>GNEM ( HIBM ) , severe , progressive myopathy cause defect biosynthetic pathway sialic acid ( SA ) . Substrate replacement potential therapeutic strategy base success replace miss SA reduce muscle disease relevant mouse model human disease . Successful use SA replacement therapy human believe depend upon provide steady , long-term exposure compound extended-release form ( Ace-ER ) , give SA 's short half-life . This Phase 3b extension study ass long-term safety Ace-ER patient participate complete UX001-CL202 , UX001-CL301 , UX001-CL203 study ; addition , efficacy 6 g/day Ace-ER evaluate GNEM patient , include able walk ≥200 6-minute walk test ( 6MWT ) ( roll subject UX001-CL301 naïve subject UX001-CL202 ) GNEM patient severe ambulatory impairment ( roll subject UX001-CL203 ) .</detailed_description>
	<mesh_term>Muscular Diseases</mesh_term>
	<mesh_term>Distal Myopathies</mesh_term>
	<criteria>Have complete UX001CL202 , UX001CL301 UX001CL203 study Willing able provide write , sign informed consent nature study explain , researchrelated procedure conduct Willing comply study procedure Female participant child‐bearing potential male participant female partner childbearing potential undergone bilateral salpingo‐oophorectomy sexually active must consent use highly effective method contraception determine site investigator ( i.e. , oral hormonal contraceptive , patch hormonal contraceptive , vaginal ring , intrauterine device , physical doublebarrier method , surgical hysterectomy , vasectomy , tubal ligation true abstinence [ line prefer usual lifestyle subject ] , mean sex subject chooses ) , period follow signing informed consent 30 day last dose study drug Females childbearing potential must negative pregnancy test Screening willing additional pregnancy test study . Females consider childbearing potential include menopause least two year , tubal ligation least one year prior Screening , total hysterectomy bilateral salpingo oophorectomy Individuals meet follow exclusion criterion eligible participate study : Ingestion NacetylDmannosamine ( ManNAc ) relate metabolite ; intravenous immunoglobulin ( IVIG ) ; anything metabolize produce SA body within 60 day prior Screening Visit Has hypersensitivity SA excipients , judgment investigator , place subject increase risk adverse effect Pregnant breastfeed Screening plan become pregnant ( self partner ) time study Use investigational product investigational medical device within 30 day prior Screening , anticipate requirement investigational agent prior completion schedule study assessment Has condition severity acuity , opinion investigator , warrant immediate surgical intervention treatment may allow safe participation study Has concurrent disease , active suicidal ideation , condition , view investigator , place subject high risk poor treatment compliance complete study , would interfere study participation would affect safety</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>GNE Myopathy</keyword>
	<keyword>GNEM</keyword>
	<keyword>Nonaka</keyword>
	<keyword>Hereditary Inclusion Body Myopathy</keyword>
	<keyword>HIBM</keyword>
	<keyword>DMRV</keyword>
	<keyword>QSM</keyword>
</DOC>